Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ralf Hosse"'
Autor:
Ralf Hosse, Federica Cavallo, Esther Bommer, Danny Gerrits, Valeria Gonzalez-Nicolini, Marina Bacac, Volker Teichgräber, Stefan Evers, Gregory O. Dugan, Tapan K. Nayak, Erwin van Puijenbroek, Inja Waldhauer, Elisabeth Husar, J. Mark Cline, Virginie Steinhart, Gonzalo Acuna, Ekkehard Moessner, Markus Neubauer, Johannes Sam, Edwin J. W. Geven, Pradeep Garg, Sabine Lang, Jehad Charo, Sara Colombetti, Christian Klein, Linda Fahrni, Anne Freimoser-Grundschober, Otto C. Boerman, Pablo Umana
Publikováno v:
mAbs
article-version (VoR) Version of Record
Mabs, 13
Mabs, 13, 1
article-version (VoR) Version of Record
Mabs, 13
Mabs, 13, 1
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here,
Autor:
Nicolini Valeria G, Amandine Ongaro, Armando G. Burgos-Rodriguez, Christopher T. Whitlow, Wei Xu, Peter N. Morcos, Peter Brünker, Sara Colombetti, Martina Carola Birk, Michael Hettich, Sabine Lang, Christine Küttel, Stella Tournaviti, Tanja Fauti, Pablo Umana, Preethi Latha Bhavani Mohan, Sylvia Herter, Thomas von Hirschheydt, Alfred Zippelius, Johannes Sam, Christina Claus, Marina Bacac, J. Mark Cline, Tamara Hüsser, Mario Perro, Reto Gianotti, Kiran Kumar Solingapuram Sai, Viola Heinzelmann-Schwarz, Matthias E. Lauer, Maurizio Ceppi, Christian Klein, Anna Maria Giusti, Anne Freimoser-Grundschober, Hofer Thomas U, Ralf Hosse, Stanford Chen, Maria Amann, Volker Teichgräber, Rosmarie Albrecht, John Challier, Christophe Prince, Ekkehard Mössner, Jörg Benz, Claudia Ferrara, David L. Caudell, Philippe Ringler, Franziska Uhlenbrock, Sandra Grau-Richards, Henning Stahlberg, Victor Levitsky, Michael Molhoj, Catherine Joseph, Wouter H. P. Driessen, Gregory O. Dugan, Sarah Diggelmann, Ramona Schlenker, Flavio Crameri
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti–4-1BB antibodies, although effective preclinically, has not advanced to phase 3 trials because
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042e824bda5fbaedcbd140cabc14302f
https://europepmc.org/articles/PMC7181714/
https://europepmc.org/articles/PMC7181714/
Autor:
Ramona Murr, Elisabetta Ada Cavalcanti-Adam, Juana Merino, Reto Gianotti, Aintzane Zabaleta, Marina Bacac, Anthony D. Ho, Martina Emde, Jose Antonio Delgado, Samuel Moser, Felipe Prosper, Lydia Jasmin Harnisch, Anna Luise Grab, Jens Hillengass, Melanie Latzko, Klaus Strein, Ralf Hosse, Tanja Fauti, Jesús F. San Miguel, Remo Lüoend, Brigitte Neuber, Bruno Paiva, Pablo Umana, Minh Diem Vu, Christian Klein, Camille Delon, Anja Seckinger, Susanne Lipp, Michael Hundemer, Laura Moreno, Dirk Hose
Publikováno v:
Cancer Cell
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3e8fb7b6e31ecaf1ebc31b68dfbe19
https://biblio.vub.ac.be/vubir/target-expression-generation-preclinical-activity-and-pharmacokinetics-of-the-bcmat-cell-bispecific-antibody-em801-for-multiple-myeloma-treatment(3de0c7eb-7a6c-49c6-ab48-956cf6c1a52a).html
https://biblio.vub.ac.be/vubir/target-expression-generation-preclinical-activity-and-pharmacokinetics-of-the-bcmat-cell-bispecific-antibody-em801-for-multiple-myeloma-treatment(3de0c7eb-7a6c-49c6-ab48-956cf6c1a52a).html
Autor:
Ekkehard Moessner, Pablo Umana, Tilman Schlothauer, Hubert Kettenberger, Lei Shi, Tina Weinzierl, Peng Wang, Natascha Rieder, Halina Trochanowska, Ralf Hosse, Carola Ries, Cuiying Shao, Katharina Wartha, Thomas Friess, Juergen Michael Schanzer, Samuel Moser, Rebecca Croasdale, Marina Bacac, Christian Klein
Publikováno v:
mAbs
The epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) play critical roles in tumor growth, providing a strong rationale for the combined inhibition of IGF-1R and EGFR signaling in cancer therapy. We descri
Autor:
Pablo Umana, Sebastian Neumann, Djamila Ouaret, Christian Klein, Walter F. Bodmer, Vaios Karanikas, Steffi Lehmann, Tanja Fauti, Oliver Ast, Mario Perro, Sara Colombetti, Ralf Hosse, Hofer Thomas U, Christiane Jaeger, Peter Bruenker, Johannes Sam, Ekkehard Moessner, Sherri Dudal, Tina Weinzierl, Sandra Grau-Richards, Teilo H Schaller, Annette Seidl, Nathalie Steinhoff, Jose Saro, Marina Bacac, Thomas von Hirschheydt, Nicolini Valeria G, Christian Gerdes
Publikováno v:
Clinical Cancer Research. 22(13)
Purpose: CEA TCB is a novel IgG-based T-cell bispecific (TCB) antibody for the treatment of CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format incorporates bivalent binding to CEA, a head-to-tail fusion of CEA-
Autor:
Katharina Wartha, Peter Brünker, Thomas Friess, Sherif Daouti, Frank Herting, Pablo Umana, Klaus Bosslet, Gary Xu, Ningping Feng, Claudia Ferrara Koller, Ralf Hosse, Packman Kathryn E, Barbara Weiser, Meher Majety, Peng Wang, Cuiying Shao, Bin Liu, Sandra Grau-Richards, Werner Scheuer, Christian Klein, Huifeng Niu, Ekkehard Mössner, Inja Waldhauer, Suzana Vega-Harring, Hadassah Sade, Thomas Weber, Valeria Runza
Publikováno v:
Molecular cancer therapeutics. 15(5)
Dysregulated cellular apoptosis and resistance to cell death are hallmarks of neoplastic initiation and disease progression. Therefore, the development of agents that overcome apoptosis dysregulation in tumor cells is an attractive therapeutic approa
Autor:
Wim J.G. Oyen, Marije I. Koenders, Otto C. Boerman, Pablo Umana, Birgitte Walgreen, Anne Freimoser-Grundschober, Tessa van der Geest, Danny Gerrits, Peter Laverman, Tapan K. Nayak, Monique M. Helsen, Christian Klein, Samantha Y.A. Terry, Inja Waldhauer, Ekkehard Moessner, Ralf Hosse
Publikováno v:
The Journal of Nuclear Medicine (1978), 56, 5, pp. 778-83
The Journal of Nuclear Medicine (1978), 56, 778-83
The Journal of Nuclear Medicine (1978), 56, 778-83
Item does not contain fulltext One of the most prominent cell populations playing a role in rheumatoid arthritis (RA) is activated fibroblast-like synoviocytes. Among many other proteins, fibroblast-like synoviocytes dominantly express fibroblast act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269a55c0f815af189f1e5f64fe6a3e3f
https://hdl.handle.net/2066/153065
https://hdl.handle.net/2066/153065
Autor:
Linda Fahrni, Sylvia Herter, Oliver Ast, Ralf Hosse, Sabine Lang, Pablo Umana, Sherri Dudal, Tanja Fauti, Wolfgang Schäfer, Christian Klein, Ekkehard Mössner, Inja Waldhauer, Christiane Neumann, Samuel Moser, Peter Brünker, Sara Colombetti, Erwin van Puijenbroek, Johannes Sam, Tina Weinzierl, Jörg T. Regula, Anne Freimoser-Grundschober, Marina Bacac
Publikováno v:
Cancer Research. 77:3629-3629
T cell bispecific antibodies that recruit and engage T cells for tumor cell killing through binding to the T cell receptor (TCR) upon binding to a tumor antigen (TA) and subsequent crosslinking have attracted broad interest. Here, we describe a novel
Autor:
Jens Fischer, Tina Weinzierl, Christian Klein, Hofer Thomas U, Werner Scheuer, Christian Gerdes, Claudio Sustmann, Mi He, Lydia Jasmin Duerner, Marina Bacac, Ralf Hosse, Inja Waldhauer, Pablo Umana, Karlheinz Zick, Ekkehard Moessner
Publikováno v:
Cancer Research. 76:2955-2955
Introduction: Trastuzumab and pertuzumab are humanized antibodies recognizing different functional HER2 epitopes. Preclinical data demonstrated strong anti-tumoral efficacy when combining them (Scheuer et al., Canc Res, 2009). The CLEOPATRA trial sho
Autor:
Pablo Umana, Ralf Hosse, Remo Lüoend, Melanie Latzko, Klaus Strein, Anne Freimoser-Grundschober, Reto Gianotti, Jörg Zielonka, Ramona Murr, Ekkehard Mössner, Christian Klein, Tea Rodriguez Diaz, Chloé Friang, Marina Bacac, Lydia Jasmin Duerner, Oliver Ast, Tanja Fauti, Camille Delon, Samuel Moser, Minh Diem Vu, Peter Bruenker, Erwin van Puijenbroek, Tina Weinzierl
Publikováno v:
Blood. 126:2998-2998
Background & Aim: T-cell bispecific antibodies (TCBs) binding to a target on tumor cells and CD3 on T cells induce potent T-cell mediated killing of cells carrying the target. In contrast to targets like e.g. CD38 or CD138, B-cell maturation antigen